CoChat

Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities

The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.

Abstract

Obesity, type 2 diabetes, and the numerous associated metabolic co-morbidities are growing global threats to public health. Despite recent progress in pharmacotherapies for metabolic diseases, the current treatment options have limited efficacy and provide mostly symptomatic relief with little or no impact on disease reversal. Thus, improved therapies are urgently needed. As a result, the scientific community has increasingly invested in leveraging new pathophysiological insights into more efficacious pharmacotherapies for metabolic complications. A heightened understanding of the large, interindividual variation in responsiveness to certain metabolic medicines combined with advances in engineering multi-agonist candidates are important steps towards this goal. Additionally, the emerging pharmacological concept of peptide-mediated targeting of small molecules for tissue-specific delivery holds promise for more powerful treatment solutions in the future. In this review, we summarize recent advances in medicinal chemistry and molecular pharmacology that have enabled the engineering of several, novel, poly-agonist drug candidates for treatment of metabolic diseases, and we discuss the recent results from clinical trials assessing the efficacy and safety of glucagon-like peptide (GLP)-1/glucagon and GLP-1/GIP co-agonists.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40265-019-01153-6

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 103 references

Research works printed but not linked: 1

  1. González-Muniesa P, et al. Obesity. Nat Rev Dis Prim. 2017;3:1–6.

Cited by

See all 18

Metadata

Authors
Petersen, J., Strømgaard, K., Frølund, B., & Clemmensen, C.
Affiliations
University of Copenhagen (DK)
Corresponding author
Clemmensen, Christoffer
Venue
Drugs
Published
2019-06-26
Volume
79
Issue
11
Pages
1187-1197
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W2954780394
Cited by
17
References
103
Citations by year
2024: 1 · 2023: 3 · 2022: 5 · 2021: 2 · 2020: 5 · 2019: 1
FWCI
2.64
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
  • Novo Nordisk Fonden (NNF17OC0026114)
  • Lundbeckfonden (R238-2016-2859)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
metabolic disorders, obesity, type 2 diabetes, tissue-specific drug delivery, drug response variability
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Clinical Trials as Topic, Drug Therapy, Combination, Gastric Inhibitory Polypeptide, Glucagon, Humans, Metabolic Diseases, Receptors, Gastrointestinal Hormone, Receptors, Glucagon, Glucagon-Like Peptide 1, Precision Medicine, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities. https://app.cochat.ai/papers/10.1007/s40265-019-01153-6
The paper
Petersen, J., Strømgaard, K., Frølund, B., & Clemmensen, C. (2019). Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities. Drugs. https://doi.org/10.1007/s40265-019-01153-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.